Omalizumab in Chronic Spontaneous Urticaria Refractory to Conventional Therapy: An Italian Retrospective Clinical Analysis with Suggestions for Long-Term Maintenance Strategies.

about

Omalizumab in Chronic Spontaneous Urticaria Refractory to Conventional Therapy: An Italian Retrospective Clinical Analysis with Suggestions for Long-Term Maintenance Strategies.

Item

http://www.wikidata.org/entity/Q55429844

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Omalizumab in Chronic Spontane ...... g-Term Maintenance Strategies.

@en

Omalizumab in Chronic Spontane ...... g-Term Maintenance Strategies.

@nl

type

Item

label

Omalizumab in Chronic Spontane ...... g-Term Maintenance Strategies.

@en

Omalizumab in Chronic Spontane ...... g-Term Maintenance Strategies.

@nl

prefLabel

Omalizumab in Chronic Spontane ...... g-Term Maintenance Strategies.

@en

Omalizumab in Chronic Spontane ...... g-Term Maintenance Strategies.

@nl

P1476

Omalizumab in Chronic Spontane ...... g-Term Maintenance Strategies.

@en

P2093

Antongiulio Demonte

http://www.w3.org/2001/XMLSchema#string

Giovanni Pellacani

http://www.w3.org/2001/XMLSchema#string

Mario B Guanti

http://www.w3.org/2001/XMLSchema#string

Patrizia Pepe

http://www.w3.org/2001/XMLSchema#string

Serena Liberati

http://www.w3.org/2001/XMLSchema#string

P2860

Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.

Systematic review of treatments for chronic spontaneous urticaria with inadequate response to licensed first-line treatments.

Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.

Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria.

Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria.

Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria.

Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.

Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.

Development, validation, and initial results of the Angioedema Activity Score.

P2888

s13555-018-0240-7

P304

291-301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13555-018-0240-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Victor Desmond Mandel

P577

2018-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104016679

http://www.w3.org/2001/XMLSchema#string

P698

29770909

http://www.w3.org/2001/XMLSchema#string

P921

An Eadailt

P932

6002323

http://www.w3.org/2001/XMLSchema#string